BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 31454760)

  • 1. Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors.
    Vogrig A; Fouret M; Joubert B; Picard G; Rogemond V; Pinto AL; Muñiz-Castrillo S; Roger M; Raimbourg J; Dayen C; Grignou L; Pallix-Guyot M; Lannoy J; Ducray F; Desestret V; Psimaras D; Honnorat J
    Neurol Neuroimmunol Neuroinflamm; 2019 Nov; 6(6):. PubMed ID: 31454760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central nervous system complications associated with immune checkpoint inhibitors.
    Vogrig A; Muñiz-Castrillo S; Joubert B; Picard G; Rogemond V; Marchal C; Chiappa AM; Chanson E; Skowron F; Leblanc A; Ducray F; Honnorat J
    J Neurol Neurosurg Psychiatry; 2020 Jul; 91(7):772-778. PubMed ID: 32312871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Ma2/Ta paraneoplastic rhombencephalitis in a patient with lung cancer responsive to anti-PD1 therapy.
    Leempoel J; Ruyssen A; Kessler R; Van Pesch V; Gille M
    Acta Neurol Belg; 2020 Apr; 120(2):451-452. PubMed ID: 31264180
    [No Abstract]   [Full Text] [Related]  

  • 4. A case series of PD-1 inhibitor-associated paraneoplastic neurologic syndromes.
    Gill A; Perez MA; Perrone CM; Bae CJ; Pruitt AA; Lancaster E
    J Neuroimmunol; 2019 Sep; 334():576980. PubMed ID: 31195181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anti-Ma2-associated encephalitis and paraneoplastic limbic encephalitis].
    Yamamoto T; Tsuji S
    Brain Nerve; 2010 Aug; 62(8):838-51. PubMed ID: 20714032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review.
    Velasco R; Villagrán M; Jové M; Simó M; Vilariño N; Alemany M; Palmero R; Martínez-Villacampa MM; Nadal E; Bruna J
    JAMA Neurol; 2021 Jul; 78(7):864-873. PubMed ID: 33720308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Motor neuron involvement in anti-Ma2-associated paraneoplastic neurological syndrome.
    Vogrig A; Joubert B; Maureille A; Thomas L; Bernard E; Streichenberger N; Cotton F; Ducray F; Honnorat J
    J Neurol; 2019 Feb; 266(2):398-410. PubMed ID: 30498914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical analysis of anti-Ma2-associated encephalitis.
    Dalmau J; Graus F; Villarejo A; Posner JB; Blumenthal D; Thiessen B; Saiz A; Meneses P; Rosenfeld MR
    Brain; 2004 Aug; 127(Pt 8):1831-44. PubMed ID: 15215214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Worsening of anti-Hu paraneoplastic neurological syndrome related to anti-PD-1 treatment: Case report and review of literature.
    Raibagkar P; Ho D; Gunturu KS; Srinivasan J
    J Neuroimmunol; 2020 Apr; 341():577184. PubMed ID: 32058173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroiditis and immune check point inhibitors: the post-marketing experience using the French National Pharmacovigilance database.
    Garon-Czmil J; Petitpain N; Rouby F; Sassier M; Babai S; Yelehe-Okouma M; Weryha G; Klein M; Gillet P
    Fundam Clin Pharmacol; 2019 Apr; 33(2):241-249. PubMed ID: 30308083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurotoxicities associated with immune checkpoint inhibitor therapy.
    Duong SL; Barbiero FJ; Nowak RJ; Baehring JM
    J Neurooncol; 2021 Apr; 152(2):265-277. PubMed ID: 33454891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan.
    Kitagataya T; Suda G; Nagashima K; Katsurada T; Yamamoto K; Kimura M; Maehara O; Yamada R; Shigesawa T; Suzuki K; Nakamura A; Ohara M; Umemura M; Kawagishi N; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Ohnishi S; Komatsu Y; Hata H; Takeuchi S; Abe T; Sakakibara-Konishi J; Teshima T; Homma A; Sakamoto N
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1782-1788. PubMed ID: 32187734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple sclerosis outcomes after cancer immunotherapy.
    Garcia CR; Jayswal R; Adams V; Anthony LB; Villano JL
    Clin Transl Oncol; 2019 Oct; 21(10):1336-1342. PubMed ID: 30788836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Ma2-Associated Limbic Encephalitis after Termination of Immune Checkpoint Inhibitor Therapy for Malignant Pleural Mesothelioma.
    Hashimoto R; Tanabe E; Otsuka Y; Yoneda Y; Kageyama Y
    Case Rep Neurol; 2021; 13(3):724-728. PubMed ID: 34950011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occurrences and Outcomes of Immune Checkpoint Inhibitors-Induced Vitiligo in Cancer Patients: A Retrospective Cohort Study.
    Babai S; Voisin AL; Bertin C; Gouverneur A; Le-Louet H
    Drug Saf; 2020 Feb; 43(2):111-117. PubMed ID: 31630381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report.
    Kopecký J; Kubeček O; Geryk T; Slováčková B; Hoffmann P; Žiaran M; Priester P
    J Med Case Rep; 2018 Sep; 12(1):262. PubMed ID: 30217214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medication-specific variations in morphological patterns of injury in immune check-point inhibitor-associated colitis.
    Isidro RA; Ruan AB; Gannarapu S; Raj D; Rahma O; Grover S; Srivastava A
    Histopathology; 2021 Mar; 78(4):532-541. PubMed ID: 32931028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-Related Thyroiditis with Immune Checkpoint Inhibitors.
    Iyer PC; Cabanillas ME; Waguespack SG; Hu MI; Thosani S; Lavis VR; Busaidy NL; Subudhi SK; Diab A; Dadu R
    Thyroid; 2018 Oct; 28(10):1243-1251. PubMed ID: 30132401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation.
    Chanson N; Ramos-Casals M; Pundole X; Suijkerbuijk K; José de Barros E Silva M; Lidar M; Benesova K; Leipe J; Acar-Denizli N; Pradère P; Michot JM; Voisin AL; Suárez-Almazor ME; Radstake TRD; Fernandes Moça Trevisani V; Schulze-Koops H; Melin A; Robert C; Mariette X; Baughman RP; Lambotte O; ; ; ; ; ;
    Eur J Cancer; 2021 Nov; 158():208-216. PubMed ID: 34452793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myositis as an adverse event of immune checkpoint blockade for cancer therapy.
    Shah M; Tayar JH; Abdel-Wahab N; Suarez-Almazor ME
    Semin Arthritis Rheum; 2019 Feb; 48(4):736-740. PubMed ID: 29909921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.